The following CpGs were used for ROC analysis: SPAG6 CpG 2, 4 and 9, PER1 CpG 1 and 2, NKX2-6 CpG 3 and 4, ITIH5 CpG 2 and 4. Only significant results are shown. AUC: Area under the curve, BC: breast cancer. The following CpGs were used for ROC analysis: SPAG6 CpG 1, 2, 4, 9 and 10, PER1 CpG 1 and 2, NKX2-6 CpG 1 and 4, ITIH5 CpG 1 and 4. Only significant results are shown. AUC: Area under the curve, BC: breast cancer. Percentages may not sum to 100% because of rounding. Figure 1 : Candidate gene validation and assay establishment. Candidate genes were identified using TCGA and assays for MSP, qMSP and pyrosequencing were designed. Assays were then evaluated for their specificity and sensitivity. As a first step in the validation of the candidates, methylation levels of all ten candidates was tested in luminal-like (MCF-7, MDA-MB-453, T-47D and ZR-75-1) and basal-like (BT-549, MDA-MB-231, HCC1806) breast cancer cell lines, reducing the potential biomarkers to only five. As a next step the remaining candidates were evaluated in a cohort of cryoconserved tissue of both healthy women (n = 5) and women with breast cancer (n = 29), which resulted in omission of a further candidate. The four remaining candidates, showing an increased methylation in breast cancer, were then tested in the serum test cohort. One of the four candidates showed not to be relevant and was not included in further analyses. ITIH5 was included at this point, as it previously showed potential in blood-based breast cancer detection and the serum validation cohort and plasma cohort were analyzed.
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